News and Media

From the garage to a COVID-19 vaccine lab

When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2 screening program in partnership with ...
Read More
| News

From the garage to a COVID-19 vaccine lab

When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2 screening program in partnership with ...
Read More
| News

Prescient Therapeutics raises $7 million to fund cancer treatment pipeline

Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The ...
Read More
| News

Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another ...
Read More
| News

Prescient Therapeutics is developing novel personalised therapies against a range of cancers – Small Caps

Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company's novel approach to treating ...
Read More
| News

Receive Email Updates

To stay fully updated on Prescient Therapeutics Corporate Activity and Company Announcements, please subscribe for up to the minute updates

WEBCAST AND MEDIA

PTX Shareholder Briefing - 4 August

PTX CEO Steven Yatomi Clarke discusses Prescient Therapeutics treatments in detail

Follow us and stay connected